Article

Mitigating regulatory risk with holistic CMC strategies

  • Martin Mewies, PhD

This article was originally published on European Biotechnology
As advanced therapeutic medicinal products (ATMPs) and other next-generation biologics move toward approval, Chemistry, Manufacturing, and Controls (CMC) continues to be the most frequent source of regulatory concern. This article highlights recurring CMC barriers and best practices to mitigate approval delays or refusals.

As more advanced therapeutic medicinal products (ATMPs) and other next-generation biologics seek regulatory approval, the development challenges these products encounter is gaining prominence. Assessments from regulatory authorities consistently show that Chemistry, Manufacturing and Controls (CMC) remains the area of greatest concern. 

Last year, the US Food and Drug Administration (FDA) published more than 200 complete response letters (CRLs) that had been issued between 2002 and 2024 for products that have since been approved, providing greater transparency into the agency’s decision-making process. Additionally, FDA has rejected or delayed several new cell and gene therapy (CGT) biologics license application (BLA) submissions due to problems with manufacturing readiness.

According to the manufacturers of these products, deficiencies included process control gaps, inadequate stability data, unvalidated analytical methods, and ongoing issues following Good Manufacturing Practice (GMP) inspections.

These CMC and GMP issues are well-documented in Europe, where most biological products and all ATMPs go through the Centralised Procedure (CP) with the European Medicines Agency (EMA). The agency has a long-established documentation framework and each product is subject to European public assessment reports (EPARs), whether approved or denied authorization. The release of the CRLs from FDA now allows observers to more rigorously assess areas of respective interest and concern between the health authorities.

We're here to help

Connect with our team today to learn more about how Cencora is helping to shape the future of healthcare.
abstract

Related solutions

CMC services
Get end-to-end Chemistry, Manufacturing, and Controls (CMC) support across product types, from early development through registration and post-approval lifecycle management.
  • Commercialization support
  • Pharma
  • Global
CMC biologics and ATMPs
Navigate evolving Chemistry, Manufacturing, and Controls (CMC) requirements for biologics and ATMPs, from development through post-approval lifecycle management.
  • Commercialization support
  • Pharma
  • Global
CMC small molecule
Meet small-molecule Chemistry, Manufacturing, and Controls (CMC) requirements, from impurity and nitrosamine evaluations to master files and site transfers.
  • Commercialization support
  • Pharma
  • Global

Related resources

Article

How digital innovation is transforming CMC

Article

Five key trends in CMC
Sotrovimab

Article

How cell and gene therapy developers can reduce risk of FDA complete response letters with proactive CMC strategies